PURPLE BIOTECH
Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. The company was founded in 2010 and is headquartered in Tel Aviv, Israel.
PURPLE BIOTECH
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2010-06-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.purple-biotech.com
Total Employee:
1+
Status:
Active
Contact:
+972-3-9333121
Total Funding:
51 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Topmunnity Therapeutics
Topmunnity Therapeutics is an oncology focused drug development company.
Current Employees Featured
Gil Efron CEO @ Purple Biotech
CEO
2022-07-01
Simcha Rock Chief Financial Officer @ Purple Biotech
Chief Financial Officer
2011-01-01
John Paul Waymack Founder & Chief Medical Officer @ Purple Biotech
Founder & Chief Medical Officer
2013-07-01
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-14 | Purple Biotech Announces Executive Leadership Changes |
Official Site Inspections
http://www.purple-biotech.com Semrush global rank: 4.03 M Semrush visits lastest month: 3.05 K
- Host name: 55.253.208.35.bc.googleusercontent.com
- IP address: 35.208.253.55
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Purple Biotech"
About us - Purple Biotech
Rock served as a strategic consultant to Purple Biotech from January 2019 until December 2019. Mr. Rock served as our Chief Financial Officer from July 2013 until December 31, 2018. Prior to joining us, Mr. Rock was a private equity …See details»
Investors - Purple Biotech
Purple Biotech Ltd.’s Board of Directors sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate …See details»
Purple Biotech GmbH
Purple Biotech (NASDAQ:PPBT) is an innovative, clinical stage, oncology-focused company. We provide cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. …See details»
Purple Biotech - LinkedIn
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s …See details»
Purple Biotech - Crunchbase Company Profile & Funding
Organization. Purple Biotech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Purple Biotech is an innovative …See details»
Purple Biotech - The Org
Purple Biotech is a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer.See details»
Purple Biotech Company Profile - Office Locations, Competitors
Oct 29, 2024 Purple Biotech (formerly known as Kitov Pharmaceuticals) is a company focusing on advancing therapies to overcome tumor immune evasion and drug resistance, to create …See details»
Purple Biotech Ltd. - AnnualReports.com
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219, …See details»
Organization: Purple Biotech - Cbonds.com
Purple Biotech. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»
CORPORATE PRESENTATION - purple-biotech.com
Purple Biotech (NASDAQ/TASE: PPBT) As of December 31, 2024 • ADS Outstanding: 2.6 M • Cash Balance: $8.2 M Well positioned to advance next clinical milestones • Two First-in-Class …See details»
Purple Biotech (TLV:PPBT) Company Profile & Description - Stock …
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its …See details»
Purple Biotech Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Purple Biotech Ltd. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, 32 news, and 3 literature, Disease Domain:Neoplasms ...See details»
Purple Biotech - Israeli Startup | Startup Nation Finder
Dec 3, 2024 Purple Biotech is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology …See details»
Purple Biotech Announces Research Collaboration with the
Feb 3, 2025 Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The …See details»
Purple Biotech to Present Data for its Tri-Specific Antibody
Oct 10, 2024 --Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been …See details»
EXECUTIVE INTERVIEW - Purple Biotech Ltd.: Developing First-In …
Purple Biotech recently acquired Immunorizon Ltd., a private company developing multi-specific T and NK cell engagers that selectively activate the immune response inside the tumor …See details»
Purple Biotech Ltd. - Cruelty Free Investing
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was …See details»
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in ...
5 days ago At AACR 2025, Purple Biotech presented final data from its randomized, controlled, open-label, multicenter Phase 2 study (NCT04731467), which established proof of concept in …See details»
CORPORATE PRESENTATION - purple-biotech.com
Purple Biotech (NASDAQ/TASE: PPBT) As of June 30, 2024 • ADS Outstanding: 29.0 M • Cash Balance: $7.3 M • Additional $2 M raised in July 2024 Strong position to reach short and mid …See details»
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in ...
5 days ago At AACR 2025, Purple Biotech presented final data from its randomized, controlled, open-label, multicenter Phase 2 study (NCT04731467), which established proof of concept in …See details»